OC5 Stock Overview
Cochlear Limited provides implantable hearing solutions for children and adults worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for OC5 from our risk checks.
Cochlear Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$194.28 |
| 52 Week High | AU$210.35 |
| 52 Week Low | AU$134.86 |
| Beta | 0.45 |
| 1 Month Change | -3.73% |
| 3 Month Change | 6.79% |
| 1 Year Change | 30.67% |
| 3 Year Change | 35.31% |
| 5 Year Change | 63.62% |
| Change since IPO | 282.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| OC5 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.0% | 2.1% | 0.5% |
| 1Y | 30.7% | -8.4% | 1.3% |
Return vs Industry: OC5 exceeded the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: OC5 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| OC5 volatility | |
|---|---|
| OC5 Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OC5 has not had significant price volatility in the past 3 months.
Volatility Over Time: OC5's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,800 | Dig Howitt | www.cochlear.com |
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Limited Fundamentals Summary
| OC5 fundamental statistics | |
|---|---|
| Market cap | €12.73b |
| Earnings (TTM) | €212.85m |
| Revenue (TTM) | €1.31b |
59.8x
P/E Ratio9.8x
P/S RatioIs OC5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OC5 income statement (TTM) | |
|---|---|
| Revenue | AU$2.15b |
| Cost of Revenue | AU$546.90m |
| Gross Profit | AU$1.60b |
| Other Expenses | AU$1.25b |
| Earnings | AU$350.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | 5.35 |
| Gross Margin | 74.56% |
| Net Profit Margin | 16.30% |
| Debt/Equity Ratio | 0% |
How did OC5 perform over the long term?
See historical performance and comparison